Corbus Pharmaceuticals Presented Data from Phase 2 Study of Anabasum for the Treatment of Systemic Sclerosis at the EULAR 2017 Annual Meeting

Business Insider—June 15, 2017

In a statement released by Corbus Pharmaceuticals Holdings, Inc., HSS rheumatologist Robert F. Spiera, MD, presented his study on systemic sclerosis at the European League Against Rheumatism Annual Meeting in Madrid, Spain.

The study is titled A Phase 2 study safety and efficacy of anabasum (JBT-101) in systemic sclerosis.

Read the full article at markets.businessinsider.com